Welcome to our dedicated page for Castle Biosciences SEC filings (Ticker: CSTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Castle Biosciences, Inc. (CSTL) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a Nasdaq-listed issuer. Castle Biosciences files reports with the U.S. Securities and Exchange Commission that cover its financial performance, governance changes, risk factors and material events related to its molecular diagnostics business in dermatologic and gastroenterological disease.
Investors can review current reports on Form 8-K, where Castle discloses items such as quarterly financial results, updated revenue guidance, the release of investor presentations and amendments to its bylaws. For example, 8-K filings describe when the company announces earnings for periods such as the quarter ended September 30, 2025, or when its board adopts amended and restated bylaws addressing stockholder meetings, director nominations, voting standards and indemnification provisions.
Alongside 8-Ks, users can access annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the SEC feed). These filings typically contain audited or reviewed financial statements, management’s discussion and analysis of results, details on Castle’s test portfolio, information about markets served and disclosures about risks associated with its diagnostics operations.
For those monitoring governance and capital structure, the SEC filings also identify Castle Biosciences’ state of incorporation (Delaware), the class of securities registered (common stock, $0.001 par value per share) and its listing on The Nasdaq Global Market under the symbol CSTL.
Stock Titan enhances this raw filing data with AI-powered summaries that explain key points in accessible language. Users can quickly see the main themes of a lengthy 10-K or 10-Q, identify notable changes in guidance or governance reported in 8-Ks, and navigate directly to sections that matter most for understanding Castle Biosciences’ molecular diagnostics business.
Castle Biosciences (CSTL) disclosed that its Chief Operating Officer reported an open-market sale of 12,678 shares of common stock on 10/31/2025 at a weighted-average price of $25.04, executed in multiple trades within a $25.00–$25.12 range. The sale was made pursuant to a Rule 10b5-1 plan adopted on March 6, 2025.
Following the transaction, the reporting person beneficially owns 27,569 shares directly and 100,937 shares indirectly through The Fritz Shorter Trust.
Castle Biosciences (CSTL): Form 4/A amendment reports that the Chief Operating Officer sold 18,007 shares of common stock on 08/27/2025 at a weighted-average price of $21.69, with trades executed between $21.24 and $21.94. The amendment clarifies the sale was made by the Fritz Shorter Trust, not directly by the executive.
Following the sale, holdings were 52,924 shares held directly and 100,937 shares held indirectly through the Trust. The filing also notes prior transfers to the Trust of 96,322 shares on March 19, 2025 and 22,622 shares on August 22, 2025.
Castle Biosciences, Inc. (CSTL) filed a Form S-8 to register 700,000 additional shares of common stock under its Castle Biosciences, Inc. 2022 Inducement Plan. The filing uses General Instruction E to register additional securities of the same class and incorporates prior S-8 filings by reference.
The company references its 2024 Form 10-K and 2025 quarterly and current reports for incorporation by reference, and lists standard exhibits including a legal opinion and auditor consent. Castle Biosciences identifies itself as an accelerated filer, and the registration statement is signed by President and CEO Derek J. Maetzold.
Castle Biosciences (CSTL) reported Q3 2025 results. Net revenues were $83.0 million versus $85.8 million a year ago, and the quarter showed a net loss of $0.5 million compared with net income of $2.3 million. For the nine months, net revenues reached $257.2 million, up from $245.8 million, while the company posted a net loss of $21.8 million versus income of $8.7 million last year.
Operating expenses rose on higher cost of sales and SG&A, and year‑to‑date amortization increased after the discontinuation of IDgenetix, which accelerated $20.1 million of expense. The balance sheet remained strong with cash and cash equivalents of $85.6 million and marketable investment securities of $202.0 million as of September 30, 2025. Year‑to‑date cash provided by operating activities was $37.4 million.
Dermatologic testing contributed $48.5 million and non‑dermatologic $34.5 million in Q3. The company closed an asset acquisition of Capsulomics (developed technology valued at $28.2 million) and entered a collaboration with SciBase. Long‑term debt stood at $10.0 million; the interest‑only period on the term loan was extended to December 1, 2026.
Castle Biosciences (CSTL) furnished an update on its business by announcing financial results for the third quarter ended September 30, 2025, via a press release attached as Exhibit 99.1. The company also made available an investor slide presentation as Exhibit 99.2.
The materials were furnished under Items 2.02 and 7.01 and are not deemed “filed” for purposes of Section 18 of the Exchange Act, nor incorporated into other filings except by specific reference.
Castle Biosciences (CSTL) CEO and President Derek Maetzold reported an open‑market sale of common stock. On 10/20/2025, he sold 1,339 shares at a weighted‑average price of $22.44, marked with transaction code S and made pursuant to a Rule 10b5‑1 plan adopted on May 8, 2025.
Following the transaction, his direct beneficial ownership stands at 62,988 shares. He also reports indirect holdings through various trusts, including 85,959 shares by DJM Grantor Retained Annuity Trust No. 5 and 52,923 shares by The Maetzold Descendants 2020 Trust. The sale price reflects multiple trades executed between $22.290 and $22.615, with the weighted‑average disclosed.
Dimensional Fund Advisors LP reported beneficial ownership of
The Schedule 13G indicates the position is held in the ordinary course of business and not to influence control of the issuer. The filing was signed by Dimensional's Global Chief Compliance Officer on
Castle Biosciences (CSTL) director and CEO Derek J. Maetzold reported a sale of 1,339 shares of common stock on
The sale was executed in multiple trades at prices ranging from $22.31 to $23.14, and the filer said they will provide detailed trade-by-trade information upon request. The Form 4 is a routine Section 16 disclosure showing an insider sale conducted under an affirmative-defense plan rather than an ad-hoc transaction.
Derek J. Maetzold, President & Chief Executive Officer and a director of Castle Biosciences, sold 1,339 shares of Castle Biosciences common stock on 09/17/2025 under a preexisting Rule 10b5-1 plan at a weighted-average price of $21.971 per share. After the sale, the filing reports Mr. Maetzold directly or indirectly beneficially owns multiple blocks of shares held in various trusts, with specific reported holdings including 65,666 shares directly and several trust holdings (for example, 52,923; 44,986; multiple 3,615–3,618 blocks; and larger grantor retained annuity trusts of 85,959; 18,718; and 44,323).
The Form 4 explains the sale was effected through multiple trades at prices ranging from $21.860 to $22.085 and that the transactions were executed pursuant to a 10b5-1 plan adopted May 8, 2025. The form is signed by an attorney-in-fact on behalf of the reporting person.
Derek J. Maetzold, President & Chief Executive Officer and a director of Castle Biosciences, Inc. (CSTL), sold 1,339 shares of the issuer's common stock on 09/02/2025 under a Rule 10b5-1 trading plan adopted May 8, 2025. The transaction executed in multiple trades produced a weighted-average sale price of $23.93 per share. Following the sale, the filing reports 67,005 shares held directly and multiple indirect trust holdings disclosed by name and amount, including 52,923 shares held by The Maetzold Descendants 2020 Trust and other family trusts and grantor retained annuity trusts. The Form 4 was signed by attorney-in-fact Frank Stokes on 09/04/2025.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
